NDC-11 (Package) (Ascending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00143-1477-25 | 00143-1477 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 26, 1974 | Feb. 18, 2014 | No Longer Used |
00143-2422-01 | 00143-2422 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2422-25 | 00143-2422 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2422-30 | 00143-2422 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2423-01 | 00143-2423 | Ondansetron Hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2423-25 | 00143-2423 | Ondansetron Hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2423-30 | 00143-2423 | Ondansetron Hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-2424-07 | 00143-2424 | Ondansetron | Ondansetron | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2008 | Dec. 31, 2014 | In Use |
00143-9022-02 | 00143-9022 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb. 10, 2022 | In Use | ||
00143-9092-01 | 00143-9092 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
00143-9093-01 | 00143-9093 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
00143-9098-01 | 00143-9098 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | July 27, 2022 | In Use | |
00143-9135-01 | 00143-9135 | Mitomycin | Mitomycin | 20.0 mg/1 | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 1, 2022 | In Use | |
00143-9136-01 | 00143-9136 | Mitomycin | Mitomycin | 40.0 mg/1 | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 1, 2022 | In Use | |
00143-9167-01 | 00143-9167 | Eribulin mesylate | ERIBULIN MESYLATE | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | June 28, 2024 | In Use | |
00143-9182-01 | 00143-9182 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 1.0 g/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Jan. 15, 2024 | In Use | |
00143-9202-01 | 00143-9202 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 7, 2007 | In Use | |
00143-9203-01 | 00143-9203 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 7, 2007 | In Use | |
00143-9204-01 | 00143-9204 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 14, 2021 | In Use | |
00143-9205-01 | 00143-9205 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 14, 2021 | In Use | |
00143-9217-01 | 00143-9217 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 30, 2017 | In Use | |
00143-9218-01 | 00143-9218 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 30, 2017 | In Use | |
00143-9219-01 | 00143-9219 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 30, 2017 | In Use | |
00143-9240-01 | 00143-9240 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Jan. 9, 2018 | In Use | |
00143-9241-01 | 00143-9241 | Bleomycin | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Jan. 9, 2018 | In Use | |
00143-9270-01 | 00143-9270 | Floxuridine | Floxuridine | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-Arterial | Feb. 15, 2018 | In Use | |
00143-9275-01 | 00143-9275 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
00143-9277-01 | 00143-9277 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
00143-9289-01 | 00143-9289 | Estradiol Valerate | Estradiol Valerate | 10.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | April 21, 2020 | In Use | ||
00143-9290-01 | 00143-9290 | Estradiol Valerate | Estradiol Valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | April 21, 2020 | In Use | ||
00143-9291-01 | 00143-9291 | Estradiol Valerate | Estradiol Valerate | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | April 21, 2020 | In Use | ||
00143-9292-01 | 00143-9292 | Thiotepa | Thiotepa | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Sept. 29, 2023 | In Use | |
00143-9306-01 | 00143-9306 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 12, 2018 | In Use | |
00143-9307-01 | 00143-9307 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 12, 2018 | In Use | |
00143-9308-01 | 00143-9308 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 12, 2018 | In Use | |
00143-9384-01 | 00143-9384 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 8, 2020 | In Use | |
00143-9385-01 | 00143-9385 | Decitabine | Decitabine | 50.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | April 15, 2022 | In Use | |
00143-9394-01 | 00143-9394 | Gemcitabine | Gemcitabine | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | June 25, 2021 | In Use | |
00143-9395-01 | 00143-9395 | Gemcitabine | Gemcitabine | 1.0 g/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | June 25, 2021 | In Use | |
00143-9428-01 | 00143-9428 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 1, 2021 | In Use | |
00143-9516-01 | 00143-9516 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
00143-9517-01 | 00143-9517 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
00143-9518-01 | 00143-9518 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
00143-9531-01 | 00143-9531 | Ifosfamide | Ifosfamide | 50.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | June 10, 2017 | In Use | |
00143-9546-01 | 00143-9546 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00143-9547-01 | 00143-9547 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00143-9548-01 | 00143-9548 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00143-9548-10 | 00143-9548 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00143-9549-01 | 00143-9549 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
00143-9549-10 | 00143-9549 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use |
Found 10,000 results in 6 milliseconds — Export these results